Humana (HUM) Stock Hits New 52-Week High
As seen on the 24/7 Wall St. homepage on November 10, 2026.
Related Market Updates
After-hours
$4.82
+9.05%
off the open $4.42
The 9.05% run came the same day Humana, a competitor, posted Q3 2026 results. Managed care names moved together into the close.
Before the move last 24 hours
-
Earnings releaseRelated company: HUM, competitor
Humana Q3 2026 earnings release
Related stocks today
Moves: Nov 6, 4:20 PM ET · Alpha Vantage quote
3 more related stocks · 4 have no US listing
Q3 2026
EPS
-$0.70
est -$1.00
+30.3%
Revenue
$41.16B
est $40.89B
+0.7%
Humana raised its full-year adjusted EPS floor to at least $9.50 from at least $9.00 after a smaller quarterly loss than Wall Street expected, with the Insurance benefit ratio landing at 93.7% versus management's own guidance of slightly above 94%. That is a rare upward revision in a group where peers keep flagging rising medical costs.
Through Clover Assistant, we are committed to delivering better clinical quality and lower total cost of care. We are pleased that this continues to show up in our results, with ~98% of our members enrolled in our 5 Star rated PPO for Payment Year 2028, alongside our third consecutive year of nation-leading HEDIS performance.
Star ratings are where Medicare Advantage bonus money is won or lost, and while CVS and Aetna fight CMS in court over their downgrades, Clover's CEO says nearly all of its membership sits in a 5-Star plan for Payment Year 2028. That locks in bonus payments at a $2 billion company whose rivals are litigating to protect theirs.
Q3 2026
EPS
$0.01
est $0.01
+0.0%
Revenue
$759M
est $738M
+2.8%
Clover Health is now running a real profit engine, turning a year-ago loss into GAAP net income of $6.4 million. Management raised the low end of every full-year 2026 target and says 2027 open enrollment is tracking well.
Gainers
Losers
General Motors shed 7.5% into the close, the worst showing across 387 priority names and nearly double the next-biggest decline. GoPro and Clover Health anchored the other end, each up more than 7.5%.
New 52-week high
$431.87
+5.4% vs prior high · 2026-09-11
Humana just set a 52-week high at $431.87, more than double its March low. Anyone who wrote off the managed care name at that bottom has missed the whole round trip.
Regular session
$4.71
-8.27%
open $5.14
An 8.3% slide to $4.72 wipes out the $5 handle on a $2.1 billion insurer, and it lands a day after the stock already shed 6.9%. Back-to-back drops like this reset the base for anyone waiting to buy.
Gainers
Losers
All three major US wireless carriers are at the bottom of the board at the open, with T-Mobile down 8.9% and AT&T and Verizon close behind. Optical names lead the other side, Applied Optoelectronics up 8.9%.
Now director at CLOVER HEALTH INVESTMENTS, CORP. /DE
Clover Health is adding boardroom muscle just as CMS and insurers fight over 2027 Medicare Advantage rates, the single variable that decides whether this $1.9 billion insurtech keeps scaling. Board additions at a company this size shift who sets the growth-versus-margin call.
Now director at CLOVER HEALTH INVESTMENTS, CORP. /DE
A former U.S. senator in the boardroom is political muscle for a $1.9 billion insurer whose entire business runs on Medicare Advantage rules written in Washington. With CMS tightening star ratings thresholds and rivals suing over methodology, Torricelli's Beltway access arrives exactly when it counts most.
Gainers
Losers
Tempus AI closed the session up 10.5%, the only double-digit move among 111 tracked names. The downside was deeper and broader: Axon, Cava and Clover Health all gave up more than 9%.